Relmada Therapeutics Inc, Camp Nine deal

Relmada reverse-merged with public shell company Camp Nine. Camp Nine issued Relmada 28.1 million shares of Camp Nine common stock to acquire 94% of the issued and outstanding equity securities of Relmada. The combined company will be named Relmada Therapeutics Inc. Relmada’s d-Methadone has completed a Phase I/IIa trial to treat painful diabetic neuropathy. Relmada has rights to the optical isomer of racemic methadone, an NMDA receptor antagonist product, from Medeor Inc. (New York, N.Y.) under a July 2012 deal. ...